Emerging Options for Patients with Atrial Fibrillation

Chairpeople:

Jeffrey Weitz,¹ John Camm²

Speakers:

Christian Ruff,³ Andreas Goette,⁴ Jack Ansell⁵

1. McMaster University, Hamilton, Ontario, Canada
2. St George’s Healthcare NHS Trust, London, UK
3. Brigham & Women’s Hospital, Boston, Massachusetts, USA
4. St Vincenz-Hospital, Paderborn, Germany
5. New York City, New York, USA

Disclosure:

Dr Jeffrey Weitz and Prof John Camm have received fees for consultancy and advisory boards from Daiichi Sankyo, Bristol-Meyers Squibb, Pfizer, Bayer, Janssen, and Boehringer Ingelheim. Dr Jeffrey Weitz and Prof John Camm have also received fees for consultancy and advisory board from Portola and Boston Scientific, respectively. Dr Christian Ruff has received fees for consultancy and advisory boards from Boehringer Ingelheim, Daiichi Sankyo, Bristol-Meyers Squibb, Alere, Beckman Coulter, and research support from Daiichi Sankyo, AstraZeneca, Bristol-Meyers Squibb, Sanofi-Aventis, Merck, Eisai, and Intarcia. Prof Andreas Goette has received honoraria from Daiichi Sankyo, whilst Dr Jack Ansell has received fees for consultancy from Daiichi Sankyo, BMS, Pfizer, Janssen, Boehringer Ingelheim, and Perosphere.

Acknowledgements:

Writing assistance was provided by Dr Juliet Bell, associated with apothecom scopemedical, Ltd.

Support:

Medical writing assistance was funded by Daiichi Sankyo. The views and opinions expressed are those of the authors, as expressed during the symposium, and not necessarily of Daiichi Sankyo.

Citation:

EMJ Cardiol. 2014;2:31-37. DOI/10.33590/emjcardiol/10311306. https://doi.org/10.33590/emjcardiol/10311306.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.